CALL/NOVO-NORDISK B/2000/0.1/20.09.24 | Market Closed - BOERSE MUENCHEN 14:27:11 2024-05-31 EDT | ||
| 0.008 EUR | -20.00% |
|
| 3 months | +33.33% | ||
| 6 months | -71.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.008 | -20.00% |
| 24-05-30 | 0.01 | +25.00% |
| 24-05-29 | 0.008 | -20.00% |
| 24-05-28 | 0.01 | +100.00% |
| 24-05-27 | 0.005 | -.--% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 02:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4V3V |
| ISIN | DE000GQ4V3V8 |
| Date issued | 2023-09-13 |
| Strike | 2,000 kr |
| Maturity | 2024-09-20 (112 Days) |
| Parity | 10 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.122 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.096 € |
| Spread % | 96.00% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
